Skip to content

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03076671
Acronym
MTMD
Enrollment
783
Registered
2017-03-10
Start date
2017-03-01
Completion date
2020-12-31
Last updated
2021-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Corticobasal Degeneration, Frontotemporal Dementia, Lewy Body Disease, Multiple System Atrophy, Parkinson Disease, Parkinsonism, Parkinsonism Vascular, Primary Progressive Aphasia, Supranuclear Palsy, Progressive, Vascular Dementia

Keywords

Palliative Care, Supportive Care, Movement Disorders, Brain Disease, Neurodegeneration, Parkinson's Disease, Alzheimer's Disease

Brief summary

This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). In September 2018, the study was amended to also include Alzheimer's disease (AD) and related disorders (Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Vascular Dementia). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

Detailed description

Parkinson's disease (PD) is the second most common neurodegenerative illness affecting approximately 1.5 million Americans and is the 14th leading cause of death in the United States. PD is traditionally described as a movement disorder with characteristic motor symptoms (e.g. tremor). However, more recent research demonstrates the impact of nonmotor symptoms such as pain, depression, and dementia on mortality, quality of life (QOL), nursing home placement and caregiver distress. Regarding models of care for PD, evidence suggests that care including a neurologist results in lower mortality and nursing home placement than care solely from a primary care physician. Unfortunately, there is also significant evidence that many of the needs most important to PD patients and their caregivers (e.g. depression, planning for the future) are poorly addressed under current models of care. Palliative care is an approach to caring for individuals with life-threatening illnesses that focuses on addressing potential causes of suffering including physical and psychiatric symptoms, psychosocial issues and spiritual needs. While developed for cancer patients, palliative care approaches have been successfully applied in other chronic progressive illnesses including heart failure and pulmonary disease. To date there have been minimal attempts to apply these principles to PD although evidence suggests that PD patients' unmet needs under current models of care may be amenable to palliative care. A small but growing cadre of centers offer outpatient palliative care for PD with early evidence of efficacy and a randomized trial of an academic-based outpatient palliative care is underway led by investigators on this proposal. While this work is critical to forwarding this field, further work is needed to provide a model that can be widely disseminated. The current proposal addresses this gap by assessing the effectiveness and feasibility of a novel community-based intervention that empowers community neurology practices to improve care for PD patients and caregivers through palliative care training, coaching and telemedicine resources. The investigators hypothesize that this intervention will improve patient QOL and caregiver burden and will prove feasible and acceptable to community providers. The investigators Specific Aims are to: 1) Determine the a) effectiveness and b) feasibility of a novel community-based outpatient palliative care intervention for PD.; 2) Describe the effects of a this intervention on patient and caregiver costs and service utilization; and 3) Identify opportunities to optimize community-based palliative care for this population by: a) describing patient and caregiver characteristics associated with intervention benefits; and b) through direct patient, caregiver and provider interviews. Innovations of the investigators approach include a novel model of providing disease-specific community-based palliative care not dependent on limited palliative specialist resources, a stepped-wedge trial design and use of telemedicine resources to provide multidisciplinary care. The research is significant because it will create a foundation for future community-based dissemination studies in PD and the broader field of palliative care. In September 2018, supplemental support from NIH was granted in order to explore outcomes among an Alzheimer's dementia population. Alzheimer's disease (AD) is the most common neurodegenerative illness affecting 10% of adults over age 65. This incurable and relentlessly progressive disease affects approximately 1.5 million Americans and is the 6th leading cause of death in the United States. Care for community-dwelling patients with AD is typically focused on the assessment and pharmacologic management of cognitive and behavioral symptoms, although there is growing recognition of the need to expand care to address other issues, including advance care planning. There is significant evidence that many of the most important needs of the AD patients and their caregivers are poorly addressed under current models of care, including management of medical and psychiatric symptoms (e.g. pain and depression), caregiver support, advance care planning, and spiritual wellbeing. Importantly, while the top goal of care for the majority of patients is avoidance of institutionalization, our current models of care invest more resources in institutionalized patients rather than proactively supporting community-dwelling individuals which may prevent institutionalization and reduce overall healthcare costs. Our supplemental study will thus additionally target this population for a 12-month period.

Interventions

BEHAVIORALPalliative Care

Palliative care training for community neurologists and use of telemedicine for team-based support of patients

Sponsors

National Institute of Nursing Research (NINR)
CollaboratorNIH
University of California, San Francisco
CollaboratorOTHER
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a stepped-wedge design, meaning that during the first year all patients enrolled will continue to receive usual care provided by their neurologist, who is also enrolled in the study. During years 2 and 3, every 6 months, 4-5 neurologists will receive training in supportive and palliative care. The timing of the training will be randomly assigned. Once their neurologist has received training, all of their enrolled patients will be switched to the intervention arm, and be eligible for additional care via telemedicine with the university supportive and palliative care team. During the final year of the study, all the neurologists will have received care, and all of their patients will be in the intervention arm. On a separate level, we will be evaluating the effects of training on the enrolled neurologists through assessments of palliative skills, knowledge, and attitudes before and after the training, as well as through qualitative interviews.

Eligibility

Sex/Gender
ALL
Age
18 Years to 105 Years
Healthy volunteers
No

Inclusion criteria

* Patients must be fluent English Speakers, * Must be over age 18, * They must meet United Kingdom (UK) Brain Bank criteria for probable PD, or * They must meet standard criteria for * progressive supranuclear palsy (PSP), * corticobasal degeneration (CBD), * multiple systems atrophy (MSA), * vascular parkinsonism, or * Lewy Body Dementia (LBD) * Alzheimer's dementia (AD) * Primary progressive aphasia * Vascular dementia. * Patients must be at high risk for poor outcomes as defined by the Brief Needs Assessment Tool (BNAT) which screens for psychosocial issues, symptoms, and caregiver burden. * Caregivers will be identified by asking the patient: Could (participant) tell us the one person who helps (participant) the most with (participant's) PD outside of clinic? * Caregivers may be self-identified in cases of severe dementia in order to obtain data relevant to this vulnerable and underrepresented group.

Exclusion criteria

* Unable or unwilling to commit to study procedures; * Presence of additional chronic medical illnesses which may require palliative services (e.g. metastatic cancer); or * Already receiving palliative care or hospice services. * Not expecting to continue care with enrolled physician for at least 6 months. The investigators have purposefully kept our inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life Alzheimer's Disease (QOL-AD)Up to 48 monthsMeasures of Quality of Life
Zarit Burden of Care Instrument (ZBI)Up to 48 monthsMeasures of Care Partner Distress

Secondary

MeasureTime frameDescription
Needs at End of Life Screening ToolUp to 12 monthsDetects and measures needs for end of life
Treatment Documentation FormUp to 48 monthsMeasures of treatments used for disease management
McGill Quality of Life Questionnaire (MQOL)Up to 48 monthsMeasures of Quality of Life
Hospital Anxiety and Depression Scale (HADS)Up to 48 monthsMeasures of mood
Edmonton Symptom Assessment Scale (ESAS_PD)Up to 48 monthsMeasures of symptom burden
Functional Assessment of Chronic Illness Therapy-Spiritual Wellbeing (FACIT-SP 12 Item)Up to 48 monthsMeasures of spiritual wellbeing
Neuropsychiatric InventoryUp to 6 monthsMeasures dementia-related symptoms
Semi-structured Qualitative InterviewAt 12 monthsMeasures of participant views on the study including their outcomes and the implementation of this model of community-based palliative care.
Montreal Cognitive Assessment (MOCA)At baselineMeasures of cognitive function
Healthcare Utilization FormUp to 48 monthsMeasures of type and frequency of healthcare utilized
Palliative Performance ScaleUp to 48 monthsMeasures of Disease Severity
Clinical Global Impression of ChangeUp to 48 monthsMeasures of change in disease burden
Prolonged Grief Questionnaire (PG-12)Up to 48 monthsMeasures of grief (sense of loss)
Modified Caregiver Strain IndexUp to 48 monthsMeasures of care partner distress

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026